Slow-disease diagnosis and treatment company Shuo Mao Technology completed tens of millions of strategic financing

is understood to have completed tens of millions of strategic financings from Schomau Technology, a slow-motion healthcare company, funded by Aptar, the world's leading provider of packaging solutions for the healthcare and consumer industries. Lanchi Ventures is an A-round investor in Shuo Mao Technology.This round of financing will be used for the promotion and commercialization of the core product, disease diagnosis and treatment management system, to establish deeper cooperation with hospitals and the exploration of business models, while increasing the strength of talent pool and echelon construction. As a strategic investor, Aptar will work with Schommo Technology in the field of digital disease management platforms and algorithms, and accelerate the development, manufacture, commercialization and supply of respiratory drugs in the market and development to digitalize drug delivery, diagnosis and patient support."Aptar, the investor in this round of financing, has a mature position in the entire value chain of global drug delivery technology, and our partnership with Aptar will help us expand and accelerate the clinical application and commercialization of Shuo Mao's innovative products and technologies, and we look forward to more in-depth and innovative exploration and cooperation between Aptar and Shuo Mao Technology in the field of digital drug and disease management in China and around the world," said Lu Liang, CEO of Shuo Mao Technology. TheWashoe Mao Technology was established in 2015, the core members are mostly from multinational pharmaceutical companies, well-known Internet companies, sanjia hospitals, scientific research institutions and so on. With chronic respiratory diseases (slow-blocking lungs and asthma), Shumao Technology has now completed the extension and penetration from the end of the patient to the end of the hospital. At the hospital level, with big data on lung function as the core, we will establish an auxiliary analysis model of common respiratory diseases, evaluate patients' conditions in real time, adjust the treatment plan of patients in a timely manner, and help hospitals and doctors improve the diagnosis and treatment ability of respiratory diseases. At the same time, it can also help doctors and medical institutions to improve the daily clinical data dimension, improve clinical efficiency and expand the path of scientific research.At the patient's end, medical-grade intelligent hardware is used to collect the out-of-hospital pathology information of patients with chronic respiratory diseases. With mobile applications, WeChat small programs to access the patient's in-hospital data, combined with individual information and professional doctor's diagnosis, give the corresponding intervention, to achieve the closed-loop service for patients with chronic diseases.Lu Liang, CEO of Shumao Technology, said that the construction of Internet medical care has become the consensus of many hospitals, which provides an opportunity for Shuo Mao Technology to open up hospitals and patients at both ends and provide systemic services to both ends. As more and more hospitals obtain Internet hospital licenses and set out to establish internal Internet hospital systems, Shuo Mao Technology has the ability to help hospitals connect patients' in-hospital data in the field of respiratory departments (slow-blocking lung) and pediatrics (asthma), providing a convenient platform for remote follow-up and disease management for patients with chronic diseases. Shuo Mao Technology has reached cooperation intention with three large hospitals in Shanghai.Shuo Mao Technology has including China's CFDA, the European Union CE, the United States FDA, Japan's Ministry of Health and Health and other regulatory authorities issued certification. The company now has a number of hardware products landing, including electronic peak speedometer, intelligent inhaler, micro-mesh netomizer, high-end nasal wash, etc. , the use of Shuo Mao products at all levels of hospitals nearly a thousand. In 2019, the company's products help primary hospitals screen more than 100,000 patients with chronic respiratory diseases. (
the official website of Shuomao Technology
)